Analysts expect FibroBiologics, Inc. to report revenue of 0.00 for Q1 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 26, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | - | - | - | - |
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect FibroBiologics, Inc. to report earnings per share of -1.28 for Q1 26, against a range of -1.40 to -1.16. The most recent reported quarter, Q2 26, came in at -0.66, a 31.2% beat against the -0.96 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.20 | -1.80 | -2.80 | -2.40 | -2.60 | -1.00 | - | -0.66 | - | - | - | - | - | - | - | |||||||||||
| High Estimate | -1.22 | -1.86 | -2.42 | -2.30 | -2.42 | -1.40 | -1.16 | -0.87 | -0.63 | -0.57 | -0.78 | -0.71 | -0.75 | -0.52 | -1.01 | |||||||||||
| Low Estimate | -1.46 | -2.02 | -2.68 | -2.68 | -2.72 | -1.56 | -1.40 | -1.05 | -0.71 | -0.61 | -0.84 | -0.83 | -0.87 | -0.62 | -1.19 | |||||||||||
| Consensus Estimate | -1.34 | -1.94 | -2.55 | -2.49 | -2.57 | -1.48 | -1.28 | -0.96 | -0.67 | -0.59 | -0.81 | -0.77 | -0.81 | -0.57 | -1.10 |